EP186/#742 Is it time to test all endometrial carcinomas for P53 mutation?
EP186/#742 Is it time to test all endometrial carcinomas for P53 mutation?
About this item
Full title
Author / Creator
Publisher
Kidlington: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
ObjectivesHistorically, p53 mutation has been considered a diagnostic marker for serous endometrial carcinoma. Of the recently adopted molecular subtypes, p53 abnormal (copy number high) is the most aggressive. The aim of this study was to explore the histologic and clinical characteristics of p53 abnormal endometrial carcinoma regardless of their...
Alternative Titles
Full title
EP186/#742 Is it time to test all endometrial carcinomas for P53 mutation?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2747710977
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2747710977
Other Identifiers
ISSN
1048-891X
E-ISSN
1525-1438
DOI
10.1136/ijgc-2022-igcs.277
